Unexpected acute renal injury after high-dose etoposide phosphate and total body irradiation in children undergoing hematopoietic stem cell transplantation.
Fiche publication
Date publication
juillet 2017
Journal
Pediatric blood & cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal, Dr POCHON Cécile
Tous les auteurs :
Cordero C, Loboda C, Clerc-Urmès I, Clément L, Pochon C, Chastagner P
Lien Pubmed
Résumé
High-dose etoposide phosphate, a water-soluble prodrug of etoposide, may be used after total body irradiation (TBI) in pediatric allogeneic bone marrow transplantation for lymphoblastic leukemia. In a retrospective study of 21 children treated at the Nancy University Hospital (2000-2014), we identified unprecedentedly an unexpectedly high incidence (57%) of acute renal injury following etoposide phosphate infusion. Patients who developed renal function impairment experienced more severe mucositis but had outcomes similar to those who did not. No risk factors were identified. We speculate that the etoposide phosphate diluent, dextran 40, may have been the causative agent in these post-TBI renal toxicity cases.
Mots clés
ALL, chemotherapy, general hematology/oncology, pharmacology, renal complications after BMT, transplantation
Référence
Pediatr Blood Cancer. 2017 Jul;: